Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,932Revenue (TTM) $M40.8Net Margin (%)--Altman Z-Score--
Enterprise Value $M-236.1EPS (TTM) $-7.4Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M53.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

TSRO is held by these investors:



TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Huber Martin H. Jr.SVP & Chief Medical Officer 2017-01-03Sell190$136.2636.46view
English Edward CVP of Finance and Admin. 2016-12-12Sell10,000$129.0544.08view
Huber Martin H. Jr.SVP & Chief Medical Officer 2016-11-02Sell327$121.2953.3view
Huber Martin H. Jr.SVP & Chief Medical Officer 2016-09-22Sell408$108.1271.98view
English Edward CV.P.Finance and Administration 2016-09-08Sell7,000$88.54110.01view
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-08-30Sell29,166$86.04116.11view
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-06-30Sell12,500$74.35150.09view
English Edward CVP of Finance & Administration 2016-06-10Sell7,000$40.75356.29view
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.19428.39view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.19428.39view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Feb 22 2017 
7 Stocks Outperforming the Market Jan 12 2017 
Steven Cohen's Assets With Highest Returns Dec 30 2016 
A Tesaro Catalyst the Markets Seem to Have Overlooked Dec 20 2016 
Pioneer Investments Continues to Buy Alibaba, 8 Others Dec 07 2016 
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards? Feb 23 2017
TESARO Announces Participation at Two Investor Conferences Feb 21 2017
AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
Clovis, Tesaro Soar on Astrazeneca Phase Three News Feb 17 2017
Tesaro downgraded by FBR & Co. Feb 16 2017
Tesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017 Feb 14 2017
Tesaro's Rumored Sale Could Fetch North Of $200 Per Share: Analysts Feb 10 2017
Leerink Cuts Tesaro To Hold After Takeover Speculation Rally Feb 10 2017
Tesaro Explores Possible Sale With Investment Bank Feb 10 2017
Tesaro Rockets To All-Time High On Rumored Takeover Interest Feb 08 2017
Tesaro shares skyrocket on report of buyout interest from drugmakers Feb 08 2017
Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources Feb 08 2017
Tesaro Announces Participation at Two Investor Conferences Feb 02 2017
Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock? Feb 01 2017
Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC... Jan 31 2017
Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool Jan 30 2017
Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 Jan 20 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)